



---

**COMMENTARY**

---

**Zero-dose or under immunized: Where should the emphasis lie?**

**Oliver Ombeva Malande<sup>1-6\*</sup>, Johanna C. Meyer<sup>4,7</sup>, Victor Eneojo Adamu<sup>5,6,8</sup>, Deogratias Munube<sup>2,3,9</sup>, Richard Muhindo<sup>10</sup>, Barnabas Kigen<sup>1</sup>, Julia Jerono Songok<sup>1</sup>, Kamulegeya John<sup>11</sup>, Keneth Mugume<sup>12</sup>, Lawrence Owino-Okongo<sup>2,13</sup>, Brian Godman<sup>4,14</sup>**

<sup>1</sup>Moi University, Department of Paediatrics and Child Health, Eldoret, Kenya

<sup>2</sup>East Africa Centre for Vaccines and Immunization (ECAVI), Kampala, Uganda

<sup>3</sup>Makerere University, Department of Paediatrics and Child Health, Kampala, Uganda

<sup>4</sup>Department of Public Health Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa

<sup>5</sup>Department of Public Health, Unicaf University, Zambia

<sup>6</sup>The Euler-Franeker Memorial University, Curaçao

<sup>7</sup>South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, Pretoria, South Africa

<sup>8</sup>School of Global Health & Bioethics, Euclid University (Pôle Universitaire Euclide)

<sup>9</sup>Mulago National Referral Hospital, Directorate of Paediatrics, Kampala, Uganda

<sup>10</sup>Makerere University, Department of Nursing, Kampala, Uganda

<sup>11</sup>Ndejje University, Faculty of Health Sciences, Kampala, Uganda

<sup>12</sup>Ministry of Health, Vaccines and Immunization Division, Kampala, Uganda

<sup>13</sup>Department of Paediatrics, Child Health, University of Nairobi, Nairobi, Kenya

<sup>14</sup>Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom

\*Corresponding author: [ombevaom@gmail.com](mailto:ombevaom@gmail.com)

**How to cite this article:**

Malande OO, Meyer JC, Adamu VE, Munube D, Muhindo R, Kigen B, Songok JJ, Mugume KJK, Owino-Okongo L, Goodman B. Zero-dose or under immunized: where should the emphasis lie? *Journal of the African Society for Paediatric Infectious Diseases*. 2024; 3:1-9. DOI: <https://doi.org/10.15641/jafspidVol3pp1-9/1732>

---

**Article Information**

Received: 27 May 2024

Accepted: 4 December 2024

**Key words**

Zero dose, under immunized, big catch up, coverage, immunization, vaccines

**Abstract**

*Vaccine preventable diseases (VPD) pose significant morbidity and mortality globally. Two years after the endorsement of Immunization Agenda 2030 (IA2030), the number of children not fully vaccinated increased from 19 million pre-COVID-19 to 25 million post-COVID, with 72% (18.2 million) of these labelled as zero-dose, i. e those who did not receive DPT 1 vaccine. While children who do not initiate vaccination early (zero-dose) may be at a greater risk of missing subsequent vaccinations, we most respectfully suggest that this term zero-dose may be problematic, lending itself to misconceptions among policy makers and health professionals. Firstly, zero-dose is currently set at six weeks DPT1 vaccination point and not at birth for children 12-23 months of age. Secondly, assessing zero-dose in children 12 to 23 months of age, delays corrective or remedial action because by month 12, the children have missed key vaccines before they are flagged as zero dosers. Thirdly, in poor settings, many children who initiate vaccination do not complete the schedule, with DPT1 coverage always higher than measles vaccine coverage. Additionally, the children in poor countries who miss the first DPT dose face similar challenges and deprivations and barriers as those who fail to complete their immunization schedule. The problems of poverty, inability to fully access immunization services, hesitant caregivers and poorly equipped immunization programs affect all children across sub-Saharan Africa and other poor countries. This review seeks to discuss the importance of looking at the entire recommended immunization schedule over and above highlighting those who miss DPT1 alone and proposes that “under-immunized” children as an entity be equally emphasized as “zero dose” children in low- and middle-income countries to ensure that adequate attention is given to both vulnerable groups.*

This article is published under the [Creative Commons License 4.0](https://creativecommons.org/licenses/by/4.0/).

---

**Concerns around the definition of zero dose**

Since the inception of the World Health Organization’s (WHO) Expanded Programme on Immunization (EPI) in 1974, significant strides in child health have been realized following the introduction and uptake of routine childhood vaccines. However, vaccine preventable diseases (VPDs) continue to cause appreciable morbidity and mortality among children, more so, in low-and middle-income countries (LMICs)(1-3). In August 2020, the 73<sup>rd</sup> World Health Assembly endorsed the Immunization Agenda 2030, a global strategy to achieve the vision of a world where everyone, everywhere, at every age fully benefits from vaccines for good health and well-being(4). Three impact goals were developed to track progress towards this vision. By 2030, the global community aims to “(1) reduce mortality and morbidity from VPDs for everyone throughout the life course; (2) leave no one behind, by increasing equitable access and use of new and existing vaccines; and (3) ensure good health and well-being for everyone by strengthening immunization within primary health care (PHC) and contributing to

universal health coverage and the sustainable development goals (SDGs)”(4). However, over 18 million infants in 2021 missed the first dose of the combination diphtheria, acellular pertussis and tetanus (DPT1) vaccine globally (5-9). These infants are defined as zero-dose children and are indicators of missed communities. The focus of the SDGs has been to ensure equity, especially when more than two thirds of zero-dose children come from families living below the recognized international poverty (5-8), and to make sure no one is left behind. Consequently, there is the need to consider communities where these children come from as part of any future strategy. Marginalized communities should have as much focus as vaccination coverage in these countries.

One of the key points in addressing concerns with VPDs in children has been to define a “*zero-dose child*”. There has been confusion between a “*child who has failed to receive any routine immunization*” versus a child who missed DPT1, with two approaches currently being applied. The first approach uses a single vaccine as a proxy for zero dose status definition. The second approach uses a given subset of vaccines in identifying the children that have missed all recommended routine vaccines (10, 11). However, consensus is now emerging that the former represents a more precise definition of a zero-dose child, while the later provides a simplified definition for the purposes of monitoring that an infant has received the DPT1 vaccine. Consequently, the focus should be on routine immunization as opposed to campaign-based immunization, as this strategy aims to estimate the reach of the programmatic measured immunization services and their performance in the communities (5, 12-15). The ultimate goal of immunization services is to reach all communities (16). While one could consider other vaccines as proxies, for example, DTP3 vaccine uptake is often the preferred indicator for global IA2030 monitoring of coverage, especially given that the coverage for other vaccines, including polio or measles, usually measures uptake through household indicator surveys that could contain a mix of routine and campaign-delivered vaccine doses (10, 11).

The high proportion of zero-dose children constituting 72% (18.2 out of 25 million in 2022) as a proportion of all children globally that should be vaccinated, emphasizes the reason why urgent strategies to address this problem are long overdue. It is indeed true that reaching zero-dose children can serve as a catalyst to enhance the uptake of additional vaccines. This is evidenced by recent surveys which showed that children either missed all vaccines or received 3 or 4 doses of vaccines, suggesting that the initiation of DPT1 offers promise for subsequent doses to be received (7, 8, 17, 18). Consequently, reaching zero-dose children is an important focus of any country immunization program that is seeking to ensure immunization coverage achieves expected targets. This is because children that receive at least one dose of scheduled vaccines will most certainly be able to receive the other doses of vaccinations. The challenge arises when we estimate zero-dosers as currently defined among children 12 to 23 months of age (11) – which is almost 11 months or more from when the 6-weeks DPT1 dose vaccine would have been missed. This bracket (12 – 23 months old children) and not 6-10 weeks (the period between DPT1 and DTP2) or 18 weeks (the period when DTP3 should have been received) adds to the confusion. Typically, zero would represent the beginning, at OPV0 (oral polio vaccine) and BCG at birth, and not at 6 weeks. Additionally, 6 weeks point is not the reference for all countries for DPT1, as some countries utilize a 2-, 3- and 4-month schedule. The very confusing nature of terminology and timing may lead to confusion in target communities and local immunization health centres.

### **Zero-dose or under immunized?**

There exists a second strong counter argument besides defining the concept of “*zero-dose*” as the focus should be on efforts to address the current decline in immunization coverage and access to services, enhanced since the start of the COVID-19 pandemic. It is believed that the many different factors (or barriers) that determine whether a child will complete the recommended immunization schedule or not, are the same ones likely to drive the number of zero-dose children. The majority of zero-dose children are currently found in LMICs, which currently account for 87% of the worldwide total of 18.2 million zero-dose children (7, 8, 15, 19). In the 2021 WHO report, where just 10 countries account for 62% of zero-dose children, and the same countries also account for 59% of the children missing out on a

measles vaccine (20). It was observed that 6 countries with large-populations contributed a large proportion of zero-dose children, namely India at 15% (2.7 million), Nigeria at 12% (2.2 million), Indonesia at 6% (1.1 million), Ethiopia at 6% (1.1 million), Philippines at 6% (1 million) and Democratic Republic of Congo at 3.8% (700,000) (20). These countries accounted for almost half of all the zero-dose children globally in 2021 (5, 7, 8, 15, 18, 19). Furthermore, these countries have many poor communities, low literacy levels, and poverty with some riddled with conflict or post conflict communities (10, 11). While children from these communities are likely to miss starting the recommended immunization schedule, they are also likely to not complete the vaccination journey(21).

These poor communities have key barriers to immunization (9, 10, 22-25). Inequities in the rates of vaccination are appreciable contributors to disparities currently seen in childhood health and survival and failure to complete immunization schedules across countries (26, 27). The factors driving this under-immunization in poor countries include transportation and difficult terrain, language difficulties, migrant refugee communities, inadequate caretaker and health care education (9, 28-30). Additional factors resulting in sub-optimal immunization programmes include religious and cultural beliefs against immunization, adolescent or young caregivers, and increasing anti-vaccine messages contributing to vaccine hesitancy (9).

Other barriers to access to immunization, including long distances to health facilities, poor road network, lack of male partner support, cultural and religious barriers, all need to be assessed for their impact on zero-dose numbers (5-8, 11, 13-15, 17, 18, 31). These factors are as much a concern not only for zero-dose children but also for the entire group of under-immunized children. Given that both a zero-dose child, and an under-immunized child, are likely to face many different barriers to access to immunization services, there is need to understand the various social, or political or economic situations and contexts in which zero-dose children or the under-immunized child and their families exist to address current concerns (5, 7, 8, 11, 12, 15, 18, 19). COVID-19 related disruptions contributed to widespread delay in vaccination, increasing the likelihood of involved children missing subsequent doses of scheduled vaccines or even defaulting the recommended schedule all together before concluding the full series of their vaccines before the second birthday (32-34).

The concern about the decline in vaccination in this vulnerable group is the largest drop witnessed in many years, arguably since the inception of the global EPI program. While there is indeed a concern that COVID-19 and associated measures played an appreciable role in the recent decline, it is important to realize that these problems existed before the COVID-19 pandemic. Indeed 19.2 million children did not complete their immunization in 2019 (35), with the COVID-19 pandemic making the situation worse. The bigger worry is not the fact that COVID-19 disruptions and associated lock-down measures caused delays and declines in immunization numbers, but that this decline is continuing (16, 36, 37). Whereas it is important to increase the number of children starting immunization and thus reduce the zero-dose numbers, there is the greater need to catch-up on the numbers of eligible children who have already missed their vaccine doses (16, 36, 37). These are the children targeted in the 'Big Catch-up' which is a coordinated effort by WHO, UNICEF and GAVI, alongside IA2030 Partnership, to support countries towards implementing immunization programmes in 2023 and beyond(38).

With Immunization Agenda 2030 (IA2030), partners and stakeholders have called on concerned governments as well as relevant role players and actors to intensify the efforts for ensuring catch-up vaccination for all eligible children. (31, 32, 39-46). The objective is to address or stop the ongoing backsliding and stagnation affecting the routine immunization programs, and to expand outreach services in the EPI programs. Consequently, expanding access to essential vaccines to underserved areas of the population to ensure coverage for all children who missed vaccines as well as implement timely campaigns to help prevent future VPD outbreaks. Additional expectations are for countries to

implement and put in place evidence-based, and people-centered plans and strategies, deliberately tailored towards building trust in vaccines and the immunization program as a whole. There is therefore a need for intensified VPD pandemic response efforts with corresponding allocation of resources and energy to support the rapid and deliberate scale-up and delivery of necessary vaccines, surveillance, cold chain capacity, healthcare worker training and social mobilization to address this critical issue. This is the time to strengthen PHC services and routine immunization as the main integral component of VPD pandemic preparedness (16, 19, 21, 47, 48).

Without effective planning and preparation, to secure and allocate the necessary financing, data management and advocacy, programs will continue to lag behind (16, 36, 37). In future, programs will continue to be strained due to shrinking budgets and low numbers and a poorly motivated healthcare work force. As we transition from the COVID-19 pandemic and its associated emergencies, projections paint a concerning picture, with countries experiencing declining budgets with smaller amounts of revenue generated and increasing borrowing costs (49-56). The recent World Bank projections show that up to 40 countries (where 29 are in the middle- and low-income category) may never even manage to return to the pre-COVID-19 pandemic county vaccine coverage rates, even by 2026 (16, 19, 21, 47, 48). This will affect government planning and domestic budgets as well as PHC services, especially immunization.

## **Conclusion**

The use of the term zero-dose, as currently defined, may easily be misunderstood and thus result in misconceptions. Zero-dose as currently set is not at birth but at the age the child receives the DPT1 vaccine. When zero-dose definition is used as currently proposed, delays in corrective or remedial response action may result since some children will have missed many vaccines before they are flagged as zero-dose children. Additionally, in most settings in SSA, a significant portion of those who start the recommended immunization schedule actually do not finish the journey. Over the years, reports on coverage and immunization levels have shown that there is usually a steady decline along the immunization journey from DPT1 to measles containing vaccine 2 (MCV2). The coverage for MCV2 is often lower than that of DPT3 and MCV1. Consequently, the under-immunized or non-immunized children should as well receive equal focus as given to zero-dose children to reduce VPDs. This way, the population of the not (fully) immunized children will be reduced.

**Contribution of Authors:** All authors contributed equally and are equally responsible for the content of the manuscript.

**Funding:** There was no funding for this project.

**Ethics approval:** Not applicable

**Competing interests:** The authors declare no competing interests

## References

1. Yaya S, Uthman OA, Okonofua F, Bishwajit G. Decomposing the rural-urban gap in the factors of under-five mortality in sub-Saharan Africa? Evidence from 35 countries. *BMC public health*. 2019;19(1):1-10.
2. WHO. Global Health Estimates: Life expectancy and leading causes of death and disability. GENEVA: WHO; 2021.
3. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Infectious Diseases*. 2017;17(11):1133-61.
4. WHO. Immunization agenda 2030: a global strategy to leave no one behind. Geneva: WHO. 2020.
5. Lindstrand A, Mast E, Churchill S, Rahimi N, Grevendork J, Brooks A, et al. Implementing the immunization agenda 2030: a framework for action through coordinated planning, monitoring & evaluation, ownership & accountability, and communications & advocacy. *Vaccine*. 2023.
6. Summan A, Nandi A, Deo S, Laxminarayan R. Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush. *Annals of the New York Academy of Sciences*. 2021;1502(1):110-20.
7. UNICEF W. Progress and challenges with achieving universal immunization coverage. Accessed 23rd July. 2020.
8. WHO U. WHO and UNICEF Estimates of National Immunization Coverage (WUENIC). 2016.
9. Malande OO, Munube D, Afaayo RN, Annet K, Bodo B, Bakainaga A, et al. Barriers to effective uptake and provision of immunization in a rural district in Uganda. *PloS one*. 2019;14(2):e0212270.
10. Wonodi C, Farrenkopf BA. Defining the Zero Dose Child: A Comparative Analysis of Two Approaches and Their Impact on Assessing the Zero Dose Burden and Vulnerability Profiles across 82 Low-and Middle-Income Countries. *Vaccines*. 2023;11(10):1543.
11. Cata-Preta BO, Santos TM, Mengistu T, Hogan DR, Barros AJ, Victora CG. Zero-dose children and the immunisation cascade: understanding immunisation pathways in low and middle-income countries. *Vaccine*. 2021;39(32):4564-70.
12. Galles NC, Liu PY, Updike RL, Fullman N, Nguyen J, Rolfe S, et al. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. *The Lancet*. 2021;398(10299):503-21.
13. Johri M, Rajpal S, Subramanian S. Progress in reaching unvaccinated (zero-dose) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys. *The Lancet Global Health*. 2021;9(12):e1697-e706.
14. Portnoy A, Resch SC, Suharlim C, Brenzel L, Menzies NA. What We Do Not Know About the Costs of Immunization Programs in Low-and Middle-Income Countries. *Value in Health*. 2021;24(1):67-9.
15. Santos TM, Cata-Preta BO, Mengistu T, Victora CG, Hogan DR, Barros AJ. Assessing the overlap between immunisation and other essential health interventions in 92 low-and middle-income countries using household surveys: opportunities for expanding immunisation and primary health care. *EClinicalMedicine*. 2021;42.
16. WHO. Immunization Agenda 2030: a global strategy to leave no one behind. Geneva: WHO. 2020.

17. Wendt A, Santos TM, Cata-Preta BO, Costa JC, Mengistu T, Hogan DR, et al. Children of more empowered women are less likely to be left without vaccination in low-and middle-income countries: A global analysis of 50 DHS surveys. *Journal of global health*. 2022;12.
18. Wigley A, Lorin J, Hogan D, Utazi CE, Hagedorn B, Dansereau E, et al. Estimates of the number and distribution of zero-dose and under-immunised children across remote-rural, urban, and conflict-affected settings in low and middle-income countries. *PLOS Global Public Health*. 2022;2(10):e0001126.
19. COVID W. pandemic leads to major backsliding on childhood vaccinations, new who, UNICEF data shows. New York & Geneva. 2021.
20. WHO. IMMUNIZATION AGENDA 2030 GLOBAL REPORT 2021 - Advancing the Immunization Agenda 2030 during the COVID-19 pandemic. Geneva: WHO 2022 May 2022.
21. Wolfson LJ, Gasse F, Lee-Martin S-P, Lydon P, Magan A, Tibouti A, et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. *Bulletin of the World Health organization*. 2008;86:27-39.
22. Zewdie A, Letebo M, Mekonnen T. Reasons for defaulting from childhood immunization program: a qualitative study from Hadiya zone, Southern Ethiopia. *BMC public health*. 2016;16(1):1-9.
23. Wiysonge CS, Uthman OA, Ndumbe PM, Hussey GD. Individual and contextual factors associated with low childhood immunisation coverage in sub-Saharan Africa: a multilevel analysis. *PloS one*. 2012;7(5):e37905.
24. Risks and challenges in Africa's COVID-19 vaccine rollout [press release]. GENEVA, 14 May 2021.
25. Masters NB, Wagner AL, Boulton ML. Vaccination timeliness and delay in low-and middle-income countries: a systematic review of the literature, 2007-2017. *Human vaccines & immunotherapeutics*. 2019;15(12):2790-805.
26. Victora CG, Requejo JH, Barros AJ, Berman P, Bhutta Z, Boerma T, et al. Countdown to 2015: a decade of tracking progress for maternal, newborn, and child survival. *The Lancet*. 2016;387(10032):2049-59.
27. Chang AY, Riumallo-Herl C, Perales NA, Clark S, Clark A, Constenla D, et al. The equity impact vaccines may have on averting deaths and medical impoverishment in developing countries. *Health Affairs*. 2018;37(2):316-24.
28. McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. *The Lancet Global Health*. 2019;7(1):e47-e57.
29. Malande OO, Munube D, Afaayo RN, Chemweno C, Nzoka M, Kipsang J, Musyoki AM, Meyer JC, Omayo LN, Owino-Okongo L. Adverse events following immunization reporting and impact on immunization services in informal settlements in Nairobi, Kenya: a prospective mixed-methods study. *Pan Afr Med J*. 2021 Oct 7;40:81. doi: 10.11604/pamj.2021.40.81.25910. PMID: 34909070; PMCID: PMC8607951.30. Malande OO. My covid-19 experience: picking up the pieces. *African Health Sciences*. 2020;20(4):1510-3.
31. Bergen N, Cata-Preta BO, Schlottheuber A, Santos TM, Danovaro-Holliday MC, Mengistu T, et al. Economic-Related Inequalities in Zero-Dose Children: A Study of Non-Receipt of Diphtheria–Tetanus–Pertussis Immunization Using Household Health Survey Data from 89 Low-and Middle-Income Countries. *Vaccines*. 2022;10(4):633.
32. Alkema L, Chou D, Hogan D, Zhang S, Moller A-B, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based

- projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. *The Lancet*. 2016;387(10017):462-74.
33. Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, et al. Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada. *BMC public health*. 2018;18(1):1-15.
34. Mutua MK, Mohamed SF, Porth JM, Faye CM. Inequities in on-time childhood vaccination: evidence from Sub-Saharan Africa. *American Journal of Preventive Medicine*. 2021;60(1):S11-S23.
35. WHO. Immunization coverage Geneva; 2020.
36. WHO. WHO vaccine-preventable diseases: monitoring system: 2020 global summary. WHO; 2020.
37. Zoumpourlis V, Goulielmaki M, Rizos E, Baliou S, Spandidos DA. [Comment] The COVID-19 pandemic as a scientific and social challenge in the 21st century. *Molecular medicine reports*. 2020;22(4):3035-48.
38. WHO. The big catch-up: an essential immunization recovery plan for 2023 and beyond. 2023.
39. AbouZahr C, De Savigny D, Mikkelsen L, Setel PW, Lozano R, Nichols E, et al. Civil registration and vital statistics: progress in the data revolution for counting and accountability. *The Lancet*. 2015;386(10001):1373-85.
40. AlShurman BA, Khan AF, Mac C, Majeed M, Butt ZA. What Demographic, Social, and Contextual Factors Influence the Intention to Use COVID-19 Vaccines: A Scoping Review. *International Journal of Environmental Research and Public Health*. 2021;18(17):9342.
41. Bamba C, Gibson M, Sowden A, Wright K, Whitehead M, Petticrew M. Tackling the wider social determinants of health and health inequalities: evidence from systematic reviews. *Journal of Epidemiology & Community Health*. 2010;64(4):284-91.
42. Barker PM, Reid A, Schall MW. A framework for scaling up health interventions: lessons from large-scale improvement initiatives in Africa. *Implementation Science*. 2015;11(1):1-11.
43. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PloS one*. 2018;13(12):e0208601.
44. Blencowe H, Cousens S, Jassir FB, Say L, Chou D, Mathers C, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. *The Lancet Global Health*. 2016;4(2):e98-e108.
45. Brenzel L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? *Vaccine*. 2015 May 7;33 Suppl 1:A93-8. doi: 10.1016/j.vaccine.2014.12.076. PMID: 25919183.
46. Buja A, Manfredi M, De Luca G, Zampieri C, Zanovello S, Perkovic D, Scotton F, Minnicelli A, De Polo A, Cristofori V, Biasi L, Baldovin T, Bertonecello C, Cocchio S, Baldo V. Using Failure Mode, Effect and Criticality Analysis to Improve Safety in the COVID Mass Vaccination Campaign. *Vaccines (Basel)*. 2021 Aug 5;9(8):866. doi: 10.3390/vaccines9080866. PMID: 34451990; PMCID: PMC8402500.
47. Anthony B, Monasch R, Lautenbach B, Gacic-Dobo M, Neill M, Karimov R, et al. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. *Bulletin of the World Health Organization*. 2009;87:535-41.
48. WHO. Global vaccine action plan: monitoring, evaluation and accountability. Secretariat Annual Report 2017. . Geneva; 2017 2017.



49. Abbas K, Procter SR, Van Zandvoort K, Clark A, Funk S, Mengistu T, et al. Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. *The Lancet Global Health*. 2020;8(10):e1264-e72.
50. Adamu AA, Jalo RI, Habonimana D, Wiysonge CS. COVID-19 and routine childhood immunization in Africa: Leveraging systems thinking and implementation science to improve immunization system performance. *International Journal of Infectious Diseases*. 2020;98:161-5.
51. Alsuhaibani M, Alaqeel A. Impact of the COVID-19 Pandemic on Routine Childhood Immunization in Saudi Arabia. *Vaccines (Basel)*. 2020 Oct 3;8(4):581. doi: 10.3390/vaccines8040581. PMID: 33022916; PMCID: PMC7711657.
52. Billon-Denis E, Tournier J-N. COVID-19 and vaccination: a global disruption. *Medecine Sciences: M/S*. 2020;36(11):1034-7.
53. Chelo D, Nguefack F, Enyama D, Nansseu R, Feudjo Tefoueyet G, Mbassi Awa HD, Mekone Nkwelle I, Nguefack-Tsague G, Ndenbe P, Koki Ndombo PO. Impact and projections of the COVID-19 epidemic on attendance and routine vaccinations at a pediatric referral hospital in Cameroon. *Arch Pediatr*. 2021 Aug;28(6):441-450. doi: 10.1016/j.arcped.2021.05.006. Epub 2021 Jun 9. PMID: 34140219; PMCID: PMC8188383.
54. González PA, Zabibdullah A, Martínez JC, Delgado RC. Exploring COVID-19 pandemic side effects: The case of routine immunization in Afghanistan. *Journal of global health*. 2022;12.
55. Hillis SD, Unwin HJT, Chen Y, Cluver L, Sherr L, Goldman PS, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. *The Lancet*. 2021;398(10298):391-402.
56. Hoang DV, Cashin J, Gribble K, Marinelli K, Mathisen R. Misalignment of global COVID-19 breastfeeding and newborn care guidelines with World Health Organization recommendations. *BMJ nutrition, prevention & health*. 2020;3(2):339.

The *Journal of the African Society for Paediatric Infectious Diseases Society (JAfSPID)* is a free, open-access, online journal. *JAfSPID* publishes a wide variety of manuscripts including full-length research articles, short research communications, review articles, commentaries, case reports, medical images, conference reports, short commentaries on a published landmark paper or report, letters to the editor and invited editorials on all aspects of infectious diseases in neonates, children, and adolescents. Contributions are reviewed by one editor. In addition, all research manuscripts, review articles, commentaries, case reports, medical images and conference reports are subjected to double-blind peer-review by at least one external, independent referee.